343.60DKK+0.82%Mkt Cap: 5.61B DKKP/E: 3.35Last update: 2026-05-21
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Pre…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap5.61B DKK
Enterprise Value4.64B DKK
Revenue (TTM)2.64B DKK
Gross Profit2.56B DKK
Net Income (TTM)1.69B DKK
Revenue/Share161.94 DKK
Last Price343.60 DKK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees300
CountryDK
SectorHealthcare
IndustryBiotechnology
ISINDK0062266474
Valuation
P/E (Trailing)3.35
P/E (Forward)15.83
PEG—
EV/EBITDA2.15
EV/Revenue1.76
P/S2.13
P/B4.90
EPS (TTM)102.68
EPS (Forward)21.70
52W Range
338.6076% of range345.20
52W High345.20 DKK
52W Low338.60 DKK
Profitability
Gross Margin96.96%
Oper. Margin-51.94%
EBITDA Margin81.76%
Profit Margin64.11%
ROE147.53%
ROA128.09%
Growth
Revenue Growth-0.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF1.71B DKK
CapEx (TTM)19.16M DKK
FCF Margin50.51%
FCF Yield23.73%
Net Debt-975.52M DKK
Net Debt/EBITDA-0.45
Balance Sheet
Debt/Equity0.09
Current Ratio13.63
Quick Ratio13.58
Book Value/Sh70.16 DKK
Cash/Share66.31 DKK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 DKK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJun 30, 2025
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)451.50 DKK
Target Range403.00 DKK – 500.00 DKK
# Analysts2
Ownership
Shares Out.16.33M
Float6.28M
Insiders61.06%
Institutions25.09%
Technical
SMA 50345.42 (-0.5%)
SMA 200409.63 (-16.1%)
Beta0.25
S&P 52W Chg28.31%
Avg Vol (30d)15.98K
Avg Vol (10d)33.53K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—